Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines

Clinical and Experimental Immunology

Volumn 112, Issue 2, 1998, Pages 172-180

  Nash, M A ^a   Lenzi, R ^a   Edwards, C L ^a   Kavanagh, J J ^a   Kudelka, A P ^a   Verschraegen, C F ^a   Platsoucas, C D ^b   Freedman, R S ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytokines; Ovarian cancer; RT PCR

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVARY CANCER; PERITONEUM EXUDATE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR;

ADENOCARCINOMA; ASCITIC FLUID; CARCINOMA; CYSTADENOCARCINOMA, SEROUS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; PHENOTYPE; POLYMERASE CHAIN REACTION; SURFACE PROPERTIES; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0031801588     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00576.x     Document Type: Article

References (45)

1. McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996; 334:1-6.
2. Ioannides CG, Freedman RS, Platsoucas CD, Rasheed S, Kim Y-P. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 1991; 146:1700-7.
3. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991; 51:4257-65.
4. Kooi S, Freedman RS, Rodriquez-Villanueva J, Platsoucas CD. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes (TIL) from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymph Cyto Res 1993; 12:429-37.
5. Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993; 151:5481-91.
6. Willemse PHB, DeVries EGE, Mulder NH, Alders JG, Bouma J, Sleijfer DT. Intraperitoneal human recombinant interferon alpha-2b in minimum residual ovarian cancer. Eur J Cancer 1990; 26:353-8.
7. Pujade-Lauraine E, Guastella JP, Colombo N et al. Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996; 14:343-50.
8. Canevari S, Stoter G, Arienti F et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87:1463-9.
9. Urba WJ, Clark JW, Steis RG et al. Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations. J Natl Cancer Inst 1989; 81:602-11.
10. Mule JJ, Schwarz AB, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor-beta inhibits the in vivo generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 1988; 26:95-100.
11. Czarniecki CW, Chiu HH, Wong GHW, McCabe SM, Palladino MA. Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988; 140:4217-23.
12. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
13. Donnet-Hughes A, Schiffrin EJ, Huggett AC. Expression of MHC antigens by intestinal epithelial cells. Effect of transforming growth factor-beta 2 (TGF-β2). Clin Exp Immunol 1995; 99:240-4.
14. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-51.
15. Marth C, Lang T, Koza A, Mayer I, Daxenbichler G. Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. Cancer Lett 1990; 51:221-5.
16. Matsuda M, Salazar F, Petersson M et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180:2371-6.
17. Moradi MM, Carson LF, Weinberg JB, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993; 72:2433-40.
18. Panek RB, Lee Y-J, Benveniste EN. TGF-β suppression of IFN-γ-induced class II MHC gene expression does not involve inhibition of phosphorylation of JAK1, JAK2, or signal transducers and activators of transcription, or modification of IFN-γ enhanced factor X expression. J Immunol 1995; 154:610-9.
19. Polyak K. Negative regulation of cell growth by TGFbeta. Biochim Biophys Acta Rev Cancer 1996; 1242:185-99.
20. Weller M, Malipiero U, Groscurth P, Fontana A. T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. Exp Cell Res 1995; 221:395-403.
21. Geng Y, Gulbins E, Altman A, Lotz M. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc Natl Acad Sci USA 1994; 1:8602-6.
22. Romano MF, Lamberti A, Petrella A, Bisogni R, Tassone P, Formisano S, Venuta S, Turco MC. IL-10 inhibits nuclear factor-κB/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. J Immunol 1996; 156:2119-23.
23. Yamamoto N, Zou J-P, Li X-F et al. Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J Immunol 1995; 154:2281-90.
24. Young MRI, Wright MA, Matthews JP, Malik I, Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol 1996; 156:1916-22.
25. Lee JD, Rhoades K, Economou JS. Interleukin-4 inhibits the expression of tumour necrosis factors α and β, interleukins 1β and -6, and interferon-gamma. Immunol Cell Biol 1994; 73:57-61.
26. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, Kiessling R. Selective expression of interleukin 10, interferon γ, and granulocyte-macrophage colony stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA 1992; 89:7708-12.
27. Bartlett JMS, Rabiasz GJ, Scott WN, Langdon SP, Smyth JF, Miller WR. Transforming growth factor-β mRNA expression and growth control of human ovarian carcinoma cells. Brit J Cancer 1992; 65:655-60.
28. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990; 50:6959-65.
29. Malik STA, Knowles RG, East N, Lando D, Stamp G, Balkwill FR. Antitumor activity of γ-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 1991; 51:6643-9.
30. Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients wich ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 1994; 167:145-60.
31. Topalian SL, Solomon D, Avis FP et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6:839-53.
32. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes (TIL). Cancer Treat Res 1996; 82:115-46.
33. Freedman RS, Edwards CL, Kavanagh JJ et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother 1994; 16:198-210.
34. Xie WQ, Rothblum LI. Rapid, small-scale RNA isolation from tissue culture cells. Biotechniques 1991; 11:324, 326-7.
35. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
36. Spagnoli GC, Juretic A, Schultz-Thater E et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Cell Immunol 1993; 146:391-405.
37. Lüscher U, Filgueira L, Juretic A, Zuber M, Lüscher NJ, Heberer M, Spagnoli GC. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 1994; 57:612-9.
38. Freedman RS, Gibbons JA, Giedlin M et al. Immunopharmacology and cytokine production of a low dose schedule of intraperitoneal administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. J Immunother 1997; 19:443-51.
39. Lin WL, Chen P-F, Freedman RS, Platsoucas CD. Fresh (uncultured) tumor-infiltrating lymphocytes (TIL) from patients with malignant melanoma or ovarian carcinoma are comprised of oligoclonal T cells. J Immunol 1943; 150:176A.
40. Kooi S, Zhang H-Z, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996; 174:116-28.
41. Bost KL, Bieligk SC, Jaffe BM. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies: tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J Immunol 1995; 154:718-29.
42. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, Strieter RM. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994; 145:18-25.
43. Lin WC, Yasumura S, Suminami Y, Sung MW, Nagashima S, Stanson J, Whiteside TL. Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol 1995; 155:4805-16.
44. Melichar B, Savary C, Kudelka AA, Verschraegen C, Kavanagh JJ, Edwards CL, Platsoucas CD, Freedman RL. Lineage negative HLA-DR positive cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res, in press.
45. Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor-β2 in malignant melanoma correlates with the depth of tumor invasion. Am J Pathol 1994; 145:97-104.